Approved IFCC recommendation on reporting results for blood glucose (abbreviated)

Paul D'Orazio, Robert W. Burnett, Niels Fogh-Andersen, Ellis Jacobs, Katsuhiko Kuwa, Wolf R. Külpmann, Lasse Larsson, Andrzej Lewenstam, Anton H J Maas, Gerhard Mager, Jerzy W. Naskalski, Anthony Okorodudu

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

In current clinical practice, plasma and blood glucose are used interchangeably with a consequent risk of clinical misinterpretation. In human blood, glucose, like water, is distributed between erythrocytes and plasma. The molality of glucose (amount of glucose per unit of water mass) is the same throughout the sample, but the concentration is higher in plasma because the concentration of water and, therefore, glucose is higher in plasma than in erythrocytes. Different devices for the measurement of glucose may detect and report fundamentally different quantities. Different water concentrations in calibrators, plasma, and erythrocyte fluid can explain some of the differences. Results of glucose measurements depend on sample type and on whether methods require sample dilution or use biosensors in undiluted samples. If the results are mixed up or used indiscriminately, the differences may exceed the maximum allowable error of glucose determinations for diagnosing and monitoring diabetes mellitus, and complicate the treatment. The goal of the IFCC Scientific Division Working Group on Selective Electrodes and Point of Care Testing (IFCC-SD, WG-SEPOCT) is to reach a global consensus on reporting results. The document recommends reporting the concentration of glucose in plasma (with the unit mmol/L), irrespective of sample type or measurement technique. A constant factor of 1.11 is used to convert concentration in whole blood to the equivalent concentration in the pertinent plasma. The conversion will provide harmonized results, facilitating the classification and care of patients and leading to fewer therapeutic misjudgments.

Original languageEnglish (US)
Pages (from-to)1573-1576
Number of pages4
JournalClinical Chemistry
Volume51
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Blood Glucose
Plasmas
Glucose
Water
Erythrocytes
Medical problems
Biosensors
Biosensing Techniques
Dilution
Blood
Patient Care
Diabetes Mellitus
Electrodes
Fluids
Monitoring
Equipment and Supplies
Testing
Therapeutics

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

D'Orazio, P., Burnett, R. W., Fogh-Andersen, N., Jacobs, E., Kuwa, K., Külpmann, W. R., ... Okorodudu, A. (2005). Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clinical Chemistry, 51(9), 1573-1576. https://doi.org/10.1373/clinchem.2005.051979

Approved IFCC recommendation on reporting results for blood glucose (abbreviated). / D'Orazio, Paul; Burnett, Robert W.; Fogh-Andersen, Niels; Jacobs, Ellis; Kuwa, Katsuhiko; Külpmann, Wolf R.; Larsson, Lasse; Lewenstam, Andrzej; Maas, Anton H J; Mager, Gerhard; Naskalski, Jerzy W.; Okorodudu, Anthony.

In: Clinical Chemistry, Vol. 51, No. 9, 09.2005, p. 1573-1576.

Research output: Contribution to journalArticle

D'Orazio, P, Burnett, RW, Fogh-Andersen, N, Jacobs, E, Kuwa, K, Külpmann, WR, Larsson, L, Lewenstam, A, Maas, AHJ, Mager, G, Naskalski, JW & Okorodudu, A 2005, 'Approved IFCC recommendation on reporting results for blood glucose (abbreviated)', Clinical Chemistry, vol. 51, no. 9, pp. 1573-1576. https://doi.org/10.1373/clinchem.2005.051979
D'Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Külpmann WR et al. Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clinical Chemistry. 2005 Sep;51(9):1573-1576. https://doi.org/10.1373/clinchem.2005.051979
D'Orazio, Paul ; Burnett, Robert W. ; Fogh-Andersen, Niels ; Jacobs, Ellis ; Kuwa, Katsuhiko ; Külpmann, Wolf R. ; Larsson, Lasse ; Lewenstam, Andrzej ; Maas, Anton H J ; Mager, Gerhard ; Naskalski, Jerzy W. ; Okorodudu, Anthony. / Approved IFCC recommendation on reporting results for blood glucose (abbreviated). In: Clinical Chemistry. 2005 ; Vol. 51, No. 9. pp. 1573-1576.
@article{1100186e77984557b1598bb542a73dfc,
title = "Approved IFCC recommendation on reporting results for blood glucose (abbreviated)",
abstract = "In current clinical practice, plasma and blood glucose are used interchangeably with a consequent risk of clinical misinterpretation. In human blood, glucose, like water, is distributed between erythrocytes and plasma. The molality of glucose (amount of glucose per unit of water mass) is the same throughout the sample, but the concentration is higher in plasma because the concentration of water and, therefore, glucose is higher in plasma than in erythrocytes. Different devices for the measurement of glucose may detect and report fundamentally different quantities. Different water concentrations in calibrators, plasma, and erythrocyte fluid can explain some of the differences. Results of glucose measurements depend on sample type and on whether methods require sample dilution or use biosensors in undiluted samples. If the results are mixed up or used indiscriminately, the differences may exceed the maximum allowable error of glucose determinations for diagnosing and monitoring diabetes mellitus, and complicate the treatment. The goal of the IFCC Scientific Division Working Group on Selective Electrodes and Point of Care Testing (IFCC-SD, WG-SEPOCT) is to reach a global consensus on reporting results. The document recommends reporting the concentration of glucose in plasma (with the unit mmol/L), irrespective of sample type or measurement technique. A constant factor of 1.11 is used to convert concentration in whole blood to the equivalent concentration in the pertinent plasma. The conversion will provide harmonized results, facilitating the classification and care of patients and leading to fewer therapeutic misjudgments.",
author = "Paul D'Orazio and Burnett, {Robert W.} and Niels Fogh-Andersen and Ellis Jacobs and Katsuhiko Kuwa and K{\"u}lpmann, {Wolf R.} and Lasse Larsson and Andrzej Lewenstam and Maas, {Anton H J} and Gerhard Mager and Naskalski, {Jerzy W.} and Anthony Okorodudu",
year = "2005",
month = "9",
doi = "10.1373/clinchem.2005.051979",
language = "English (US)",
volume = "51",
pages = "1573--1576",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "9",

}

TY - JOUR

T1 - Approved IFCC recommendation on reporting results for blood glucose (abbreviated)

AU - D'Orazio, Paul

AU - Burnett, Robert W.

AU - Fogh-Andersen, Niels

AU - Jacobs, Ellis

AU - Kuwa, Katsuhiko

AU - Külpmann, Wolf R.

AU - Larsson, Lasse

AU - Lewenstam, Andrzej

AU - Maas, Anton H J

AU - Mager, Gerhard

AU - Naskalski, Jerzy W.

AU - Okorodudu, Anthony

PY - 2005/9

Y1 - 2005/9

N2 - In current clinical practice, plasma and blood glucose are used interchangeably with a consequent risk of clinical misinterpretation. In human blood, glucose, like water, is distributed between erythrocytes and plasma. The molality of glucose (amount of glucose per unit of water mass) is the same throughout the sample, but the concentration is higher in plasma because the concentration of water and, therefore, glucose is higher in plasma than in erythrocytes. Different devices for the measurement of glucose may detect and report fundamentally different quantities. Different water concentrations in calibrators, plasma, and erythrocyte fluid can explain some of the differences. Results of glucose measurements depend on sample type and on whether methods require sample dilution or use biosensors in undiluted samples. If the results are mixed up or used indiscriminately, the differences may exceed the maximum allowable error of glucose determinations for diagnosing and monitoring diabetes mellitus, and complicate the treatment. The goal of the IFCC Scientific Division Working Group on Selective Electrodes and Point of Care Testing (IFCC-SD, WG-SEPOCT) is to reach a global consensus on reporting results. The document recommends reporting the concentration of glucose in plasma (with the unit mmol/L), irrespective of sample type or measurement technique. A constant factor of 1.11 is used to convert concentration in whole blood to the equivalent concentration in the pertinent plasma. The conversion will provide harmonized results, facilitating the classification and care of patients and leading to fewer therapeutic misjudgments.

AB - In current clinical practice, plasma and blood glucose are used interchangeably with a consequent risk of clinical misinterpretation. In human blood, glucose, like water, is distributed between erythrocytes and plasma. The molality of glucose (amount of glucose per unit of water mass) is the same throughout the sample, but the concentration is higher in plasma because the concentration of water and, therefore, glucose is higher in plasma than in erythrocytes. Different devices for the measurement of glucose may detect and report fundamentally different quantities. Different water concentrations in calibrators, plasma, and erythrocyte fluid can explain some of the differences. Results of glucose measurements depend on sample type and on whether methods require sample dilution or use biosensors in undiluted samples. If the results are mixed up or used indiscriminately, the differences may exceed the maximum allowable error of glucose determinations for diagnosing and monitoring diabetes mellitus, and complicate the treatment. The goal of the IFCC Scientific Division Working Group on Selective Electrodes and Point of Care Testing (IFCC-SD, WG-SEPOCT) is to reach a global consensus on reporting results. The document recommends reporting the concentration of glucose in plasma (with the unit mmol/L), irrespective of sample type or measurement technique. A constant factor of 1.11 is used to convert concentration in whole blood to the equivalent concentration in the pertinent plasma. The conversion will provide harmonized results, facilitating the classification and care of patients and leading to fewer therapeutic misjudgments.

UR - http://www.scopus.com/inward/record.url?scp=24144459072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144459072&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.051979

DO - 10.1373/clinchem.2005.051979

M3 - Article

VL - 51

SP - 1573

EP - 1576

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 9

ER -